If you’ve searched for weight-loss options lately, you’ve probably seen the name retatrutide come up alongside semaglutide and tirzepatide. It’s generating a lot of buzz for one reason: in trial data, it’s producing more weight loss than anything that’s come before it. But there’s an important catch — you can’t get it yet. Here’s what it actually is, how it compares to the medications we do prescribe today, and when that might change.
The quick answer
Retatrutide is an investigational weight-loss medication, not yet FDA-approved, that has shown the largest average weight loss of any GLP-1-class drug studied to date — up to 28.7% of body weight in a 68-week trial. It works by targeting three hormone receptors instead of one or two. It is not available by prescription anywhere in 2026, including at Total Medical & Wellness. If you’re ready to start treatment now, semaglutide and tirzepatide remain the real, available options — and we prescribe both.
What is retatrutide?
Retatrutide is a triple-hormone-receptor agonist. Where semaglutide (the active ingredient in Ozempic® and Wegovy®) targets the GLP-1 receptor alone, and tirzepatide (Mounjaro®, Zepbound®) targets both GLP-1 and GIP receptors, retatrutide adds a third target: the glucagon receptor. Glucagon receptor activation appears to increase how much fat the liver burns for energy — a mechanism the other two medications don’t have — which is the leading theory for why retatrutide is outperforming them in trials.
Head-to-head: how much weight can you lose?
In the Phase 3 TRIUMPH-4 trial (results reported December 2025, 445 participants with obesity or overweight and knee osteoarthritis, 68 weeks), the 12 mg dose of retatrutide produced an average weight loss of 28.7% of body weight — about 32.3 kg (71.2 lbs). Here’s how that stacks up against the medications available today, using the same landmark trial data cited throughout our site:
| Medication | Mechanism | Avg. Weight Loss | Trial Duration |
|---|---|---|---|
| Semaglutide (2.4 mg) | GLP-1 only | −13.7% | 72 weeks (SURMOUNT-5) |
| Tirzepatide | Dual GIP + GLP-1 | −20.2% | 72 weeks (SURMOUNT-5) |
| Retatrutide (12 mg) | Triple GIP + GLP-1 + Glucagon | −28.7% | 68 weeks (TRIUMPH-4) |
These numbers come from different trials studying different populations, so they’re not a perfect apples-to-apples comparison — but the pattern is consistent with what researchers expected: adding a third hormone pathway is producing meaningfully greater average weight loss.
Is retatrutide available yet?
No. As of 2026, retatrutide remains investigational — it has not been approved by the FDA, and it cannot be legally prescribed outside of an active clinical trial. Based on the current trial timeline, an FDA submission isn’t expected until late 2026 or early 2027, with approval realistically landing sometime in late 2027 at the earliest. Additional TRIUMPH trials are still underway or reporting results throughout 2026, studying retatrutide for type 2 diabetes, cardiovascular outcomes, and other conditions.
Be cautious of anyone offering retatrutide for sale or “compounded” outside of a legitimate clinical trial — an unapproved drug obtained this way carries real safety and quality risks.
Side effects & safety data so far
In the TRIUMPH-4 trial, the most common side effects were consistent with what we already see from GLP-1-class medications: nausea (43%), diarrhea (33%), and vomiting (21%), most often during dose increases. One newer finding worth knowing about: at the highest (12 mg) dose, roughly 21% of participants reported dysesthesia — an abnormal skin sensation such as tingling or burning — generally described as mild. This is the kind of tradeoff that a longer approval and monitoring process exists to evaluate carefully before a medication reaches the public.
What this means if you’re ready to start now
We understand the appeal of “the strongest option available.” But the honest answer is that the strongest option isn’t available — and won’t be for at least another year, likely longer. If you’re dealing with stubborn weight, low energy, or a stalled metabolism today, semaglutide and tirzepatide are real, FDA-approved, and available right now, with years of real-world data behind them. Our approach at Total Medical & Wellness starts with lab work and a full health review, then matches you to the medication — and dose — that fits your goals, tolerance, and history, with monitoring throughout. You can read more about how we compare semaglutide and tirzepatide or explore our medical weight loss program in Glendale.
When retatrutide does become available, we’ll be watching closely — and this article will be one of the first things we update.
Frequently asked questions
Can I get a retatrutide prescription right now?
No. Retatrutide is not FDA-approved and cannot be legally prescribed outside of an active clinical trial as of 2026. Any source offering it for direct sale or compounding outside a trial is not a legitimate, regulated option.
How is retatrutide different from tirzepatide?
Tirzepatide targets two hormone receptors (GLP-1 and GIP). Retatrutide adds a third: the glucagon receptor, which appears to increase fat burning in the liver. In trial data, that third mechanism is associated with greater average weight loss.
When will retatrutide be FDA-approved?
Based on the current trial timeline, an FDA submission isn’t expected until late 2026 or early 2027, with approval estimated for late 2027 at the earliest. These timelines can shift as trial results continue to report throughout 2026.
What can I take instead of retatrutide today?
Semaglutide and tirzepatide are both FDA-approved, available now, and prescribed at Total Medical & Wellness as part of a medically supervised weight-loss program. Your provider can help determine which one fits your goals and health history.
Ready to Start With What’s Actually Available Today?
Retatrutide may be the future of medical weight loss — but you don’t have to wait to start. Semaglutide and tirzepatide are real, proven, and available now, prescribed and monitored by a provider who knows your history.
Book your weight-loss consultation at Total Medical & Wellness in Glendale →
Or call us directly at (623) 259-6900.
Serving Glendale, Peoria, Surprise, and the greater Phoenix West Valley.
Written by Jess Morgan, FNP-C · Total Medical & Wellness · July 2026
This article is for educational purposes and does not constitute medical advice. Retatrutide is investigational and not FDA-approved; information is based on published trial data and may change as research continues. Individual results vary. Medication decisions should be made with a licensed provider who knows your history. A clinical evaluation is required to determine candidacy.
